Parameter | No. of patients (%) | Pvalue | |
---|---|---|---|
 | EOC w/ CNS metastases | EOC w/o CNS metastases |  |
Age (yrs) | Â | Â | 0.599 |
  <60 | 16 (55.2) | 15 (48.4) |  |
  > = 60 | 13 (44.8) | 16 (51.6) |  |
FIGO stage | Â | Â | 0.666 |
  1,2 | 3 (10.3) | 2 (6.5) |  |
  3,4 | 26 (89.7) | 29 (93.5) |  |
Pathology of primary cancer |  | 0.979†| |
  Serous | 16 (55.2) | 17 (54.8) |  |
  Mucinous | 2 (6.9) | 2 (6.5) |  |
  Endometrioid | 2 (6.9) | 2 (6.5) |  |
  Clear cell | 1 (3.4) | 2 (6.5) |  |
  Mixed epithelial | 5 (17.2) | 5 (16.1) |  |
  Undifferentiated | 3 (10.3) | 3 (9.7) |  |
Histological grade* | Â | 0.724 | |
  1,2 | 5 (21.7) | 4 (16.7) |  |
  3, | 18 (78.3) | 20 (83.3) |  |
Extent of surgical resection | Â | 0.572 | |
  TAH + BSO | 23 (79.3) | 26 (83.9) |  |
  Limited | 5 (17.2) | 5 (16.1) |  |
  Biopsy | 1 (3.4) | 0 (0) |  |
Lymph node metastasis | Â | 0.313 | |
  Yes | 18 (62.1) | 23 (74.2) |  |
  No | 11 (37.9) | 8 (25.8) |  |
Ascites at the time of primary surgery | 0.650 | ||
  Yes | 19 (46.3) | 22 (52.6) |  |
  No | 10 (53.7) | 9 (47.4) |  |
Adjuvant therapy | Â | Â | 0.674 |
  Chemotherapy | 25 (86.2) | 24 (77.4) |  |
  Chemotherapy + Radiotherapy | 3 (10.3) | 5 (16.1) |  |
  None | 1 (3.4) | 2 (6.5) |  |
Platinum sensitivity | Â | 0.516 | |
  Sensitive | 16 (57.1) | 19 (65.5) |  |
  Resistant | 12 (42.9) | 10 (34.5) |  |
CD133 expression | Â | 0.018 | |
  Negative | 15 (51.7) | 25 (80.6) |  |
  Positive | 14 (48.3) | 6 (19.4) |  |